Skip to main content
SpringerLink
Log in

Dexmethylphenidate: profile report

  • New Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Keating GM, Figgitt DP. Dexmethylphenidate. Drugs 2002: 62(13): 1899–1904

    Article  PubMed  CAS  Google Scholar 

  2. Stein MA. Dexmethylphenidate: a viewpoint. Drugs 2002: 62(13): 1905–1908

    Article  Google Scholar 

  3. Arnold LE. Dexmethylphenidate: a viewpoint. Drugs 2002: 62(13): 1905–1908

    Article  Google Scholar 

  4. Brown RT, Freeman WS, Petrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001 Mar; 107(3): E43

    Article  PubMed  CAS  Google Scholar 

  5. Committee on Quality Improvement, Subcommittee on Attention-Deficity/Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics 2000 May; 105(5): 1158–70

    Article  Google Scholar 

  6. Rappley MD. Safety issues in the use of methylphenidate: an American perspective. Drug Saf 1997 Sep; 17(3): 143–8

    Article  PubMed  CAS  Google Scholar 

  7. Srinivas NR, Hubbard JW, Quinn D, et al. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharamcol Ther 1992 Nov; 52: 561–8

    Article  CAS  Google Scholar 

  8. Novartis. Focalin™ dexmethylphenidate hydrochloride tablets: prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com [Accessed 2002 May 15]

  9. Conners CK, Casat C, Coury D, et al. Randomized trial of dexmethylphenidate hydrochloride (Focalin™) and racemic methylphenidate hydrochloride (d, l-MPH) in children with ADHD [abstract no. 345 and poster]. American Psychiatric Assocation 2002 Annual Meeting; 2002 May 18–23; Philadelphia (PA).

    Google Scholar 

  10. Celgene Corporation. Attenade™ (d-threo-Methylphenidate HCl) Tablets. Data on file. 2002

  11. Novartis. Focalin™ product monograph. 2002

  12. West SA, Johnson D, Wigal S, et al. A double-blind, randomized, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride (Focalin™) in children with symptoms of attention-deficit/hyperactivity disorder (ADHD) [abstract no. 341 and poster]. American Psychiatric Assocation 2002 Annual Meeting; 2002 May 18–23; Philadelphia (PA).

    Google Scholar 

  13. Silva R, Tilker H, Cecil Jr J, et al. Open-label pilot study of dexmethylphenidate in children with ADHD [abstract no. P19 and poster]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2001 Oct 23–28; Honolulu (HI).

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dexmethylphenidate: profile report. Drugs Ther. Perspect 18, 3–6 (2002). https://doi.org/10.2165/00042310-200218110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218110-00002

Keywords

Search

Navigation